develops, produces, and markets drugs or pharmaceuticals licensed for use as medications
Bayer investor Deka takes a stand against CEO in annual vote: Bayer shareholder Deka Investment said on Friday it would not join other large investors in ...
reuters.com/business/healthcare-pharmaceuticals/bayer-investor-deka-takes-stand-against-ceo-annual-vote-2024-04-26/
Quick Glance: Successful Vote of Confidence for Bayer CEO
- Bayer CEO Bill Anderson emerges victorious in a vote of confidence at his first annual general meeting despite a challenge from Deka Investment.
- Investors representing 91.69% of equity capital voted in favor of Anderson and his top management team.
- The voting process at German annual general meetings is symbolic and serves as a reflection of investor sentiment.
- Anderson defends the decision to suspend the company's breakup and pledges to focus on drug development and legal matters.
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth: Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research ...
reuters.com/business/healthcare-pharmaceuticals/regeneron-collaborate-gene-editing-therapies-with-doudna-founded-mammoth-2024-04-25/
US FDA approves Pfizer's gene therapy for rare bleeding disorder
reut.rs/3UAkIsM
Quick Glance: FDA approves Pfizer’s gene therapy for hemophilia B
- The FDA has approved Pfizer's first gene therapy drug for a rare inherited bleeding disorder.
- Beqvez, a unique gene therapy drug by Pfizer, has been approved for adults with moderate to severe hemophilia B.
- The drug enables patients to produce Factor IX themselves to prevent and control bleeding.
- Pfizer is competing with a similar treatment from CSL Behring and planning more gene therapies for various genetic disorders.
Sanders launches Senate investigation into ‘outrageously high’ pricing of Ozempic, Wegovy
cnn.com/2024/04/24/health/senate-ozempic-wegovy-price/
Merck raises 2024 profit forecast on surging sales of cancer drug Keytruda: Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of ...
reuters.com/business/healthcare-pharmaceuticals/merck-raises-2024-profit-forecast-strong-cancer-hpv-drugs-sales-2024-04-25/
Quick Glance: Merck boosts 2024 profit outlook due to Keytruda sales
- Merck & Co. raises annual profit and revenue forecasts based on double-digit growth for the blockbuster cancer drug Keytruda.
- Sales for 2024 are estimated to be between $63.1 billion and $64.3 billion, an increase from the previous forecast.
- Keytruda recorded $6.95 billion in sales in the first quarter, a 20% increase from the previous year.
- Merck also saw strong growth with its vaccine Gardasil, the drug Vaxneuvance, and a successful acquisition of Harpoon Therapeutics in the first quarter of 2024.
Scholz Gets Another Pharma Boost With New Merck KGaA Site: Merck KGaA became the latest pharma company to begin construction of a new center in Germany ...
bloomberg.com/news/articles/2024-04-25/scholz-gets-another-pharma-boost-with-new-merck-kgaa-site
AstraZeneca leaps after smashing first-quarter forecasts: AstraZeneca sailed past market expectations for quarterly revenue and profit on Thursday ...
reuters.com/business/healthcare-pharmaceuticals/astrazeneca-beats-first-quarter-revenue-profit-estimates-2024-04-25/
Drugmaker AbbVie expects Humira volume erosion to worsen: AbbVie expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent ...
reuters.com/business/healthcare-pharmaceuticals/abbvie-raises-annual-profit-forecast-strong-skyrizi-sales-2024-04-26/
Pfizer vs Moderna battle over COVID vaccine patents begins in UK: Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key ...
reuters.com/business/healthcare-pharmaceuticals/pfizer-vs-moderna-battle-over-covid-vaccine-patents-begins-uk-2024-04-23/
Sanofi profit slips on generic competition and currency effects: Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to ...
reuters.com/business/healthcare-pharmaceuticals/sanofi-q1-profit-slips-generic-competition-forex-effects-2024-04-25/
Quick Glance: Sanofi Struggles with Profit Decline due to Competition and Currency Effects
- In the first quarter, Sanofi's operating income decreased by 14.7%, primarily due to currency effects and competitive pressures on their multiple sclerosis drug Aubagio, despite the increase in sales of the anti-inflammatory drug Dupixent.
- The company emphasized the forecast that adjusted earnings per share (EPS) for 2024 are expected to decrease by a low single-digit percentage, excluding currency fluctuations.
- During a media briefing, Finance chief Francois-Xavier Roger highlighted the impact of the decline in the Argentine Peso on first-quarter international sales.
- Since unexpectedly abandoning the 2025 margin targets last October under a plan to boost spending on drug development, CEO Paul Hudson has been working to restore investor confidence in the company's drug pipeline.
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
reuters.com/business/healthcare-pharmaceuticals/abbvies-skin-disease-drug-found-be-more-effective-than-regenerons-dupixent-study-2024-04-25/
Sanofi (SAN FP) Asks Banks to Pitch Roles for $20 Billion OTC Spinoff: French drugmaker Sanofi has asked banks to pitch for roles on the separation of its ...
bloomberg.com/news/articles/2024-04-23/sanofi-is-said-to-ask-banks-to-pitch-for-20-billion-otc-spinoff
Alzheimer's drug adoption in US slowed by doctors' skepticism: Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's ...
reut.rs/3Wbq0wc
How Novartis Rode Two Blockbusters To A Three-Day Sprint: Novartis stock jumped Tuesday after the drugmaker topped first-quarter sales and earnings forecasts ...
investors.com/news/technology/novartis-stock-novartis-earnings-q1-2024/
Quick Glance: Positive Quarterly Results Lead to Guidance Increase at Novartis
- Novartis raises its annual guidance following a successful first quarter.
- Revenue increased by 10% to $11.83 billion, with adjusted operating income growing by 16% to $4.54 billion.
- CEO Vas Narasimhan is focusing more on drug development and has been active in mergers and acquisitions.
- Novartis has secured promising drugs, including an experimental prostate cancer drug from Arvinas and the company MorphoSys, which develops cancer treatments, for 2.7 billion euros.
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology: GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday ...
reuters.com/business/healthcare-pharmaceuticals/glaxosmithkline-sues-pfizer-biontech-over-covid-19-vaccine-technology-2024-04-25/
Alzheimer's drug adoption in US slowed by doctors' skepticism: Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's ...
reuters.com/business/healthcare-pharmaceuticals/alzheimers-drug-adoption-us-slowed-by-doctors-skepticism-2024-04-23/
Quick Glance: Alzheimer's Drug Uptake Hindered by Doctors' Skepticism in US
- The first drug to slow the progression of Alzheimer's, Leqembi by Eisai and Biogen, is facing resistance in the US from doctors who believe the treatment is futile.
- The requirements of Leqembi, such as additional diagnostic tests, twice-monthly infusions, and regular brain scans, have led to slow adoption as many doctors express concerns about efficacy, cost, and risks.
- Despite FDA approval and proven benefits in clinical trials, many doctors still have reservations about Leqembi, hindering the widespread use of the drug.
- The companies behind Leqembi are working to improve physician and patient education to increase acceptance of the medication, aiming to treat 100,000 patients by 2026.
Bristol Myers Squibb drafts contingency plans for US restrictions on Chinese pharma
ft.com/content/f3b5f2e5-1abc-4848-8ff2-66891d5f5984
Bankruptcy allowed Mallinckrodt to end Acthar royalties, 3rd Circ. rules: Mallinckrodt's bankruptcy permitted the drug company to end a perpetual royalty ...
reuters.com/legal/litigation/bankruptcy-allowed-mallinckrodt-end-acthar-royalties-3rd-circ-rules-2024-04-25/
Gilead posts quarterly loss on acquisition charge, revenue rises 5%: Gilead Sciences reported a first-quarter loss on Thursday after taking a $3 ...
reuters.com/business/healthcare-pharmaceuticals/gilead-posts-quarterly-loss-revenue-rises-5-2024-04-25/
Plaintiffs' lawyers chosen to lead Ozempic litigation: A federal judge has appointed eight plaintiffs' lawyers to leadership roles in federal mass tort ...
reuters.com/legal/litigation/plaintiffs-lawyers-chosen-lead-ozempic-litigation-2024-04-24/
Ozempic and Wegovy, the diabetes and weight-loss drugs, have soared to celebrity status in the U.S. But Novo Nordisk, the Danish company behind them ... Show more
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy - The New York Times
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy - The New York Times
Haleon names Dawn Allen as CFO: Consumer healthcare firm Haleon said on Wednesday that Dawn Allen has been appointed as its new chief financial officer ...
reuters.com/business/healthcare-pharmaceuticals/haleon-names-dawn-allen-cfo-2024-04-24/
3 Octapharma Plasma centers in Columbus among those across U.S. closed by 'network issues'
dispatch.com/story/news/local/2024/04/19/network-issues-close-octapharma-plasma-centers-in-columbus-and-across-united-states/73377703007/
Pharma groups warn of supply crunch over China spying law: Factory inspectors refuse to visit country over fears they could fall foul of tightened rules
ft.com/content/1d52d75f-5b54-4c27-bdd4-65409f64c64a
US CDC warns of harmful reactions to fake Botox injections: The U.S. Centers for Disease Control and Prevention (CDC) on Tuesday alerted clinicians about risks ...
reuters.com/business/healthcare-pharmaceuticals/us-cdc-warns-harmful-reactions-fake-botox-injections-2024-04-23/
German watchdog approves Novo's acquisition of Cardior Pharmaceuticals: The German cartel office has approved a deal by Denmark's Novo Nordisk to purchase ...
reuters.com/business/healthcare-pharmaceuticals/german-watchdog-approves-novos-acquisition-cardior-pharmaceuticals-2024-04-18/
BASF CEO bids farewell with drop in Q1 earnings: Germany's BASF posted a drop in first-quarter adjusted earnings and sales on Thursday ...
reuters.com/business/basf-post-slight-q1-earnings-drop-beats-forecast-2024-04-25/
Biosimilars 102: Interchangeability, Extrapolation, and Immunogenicity -- A Regulatory Process Primer
medscape.org/viewarticle/999867
Bayer, Nestlé, Unilever and Other Multinationals Cut Back in Africa: After decades of optimism about the region, global giants such as Bayer ...
bloomberg.com/news/features/2024-04-17/bayer-nestle-unilever-and-other-multinationals-cut-back-in-africa
Paid articlePaid
BREAKING: FTSE 100 hits fresh record high at the open as European markets rise European markets live updates: stocks, news, PMI data and earnings
Cigna to offer Humira rivals with $0 copay at specialty pharmacy: Cigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with ...
reuters.com/business/healthcare-pharmaceuticals/cigna-offer-humira-rivals-with-0-copay-specialty-pharmacy-2024-04-25/
India's Biocon developing its own version of Wegovy, clinical trial likely next year
reuters.com/business/healthcare-pharmaceuticals/indias-biocon-developing-its-own-version-wegovy-clinical-trial-likely-next-year-2024-04-18/
Quick Glance: Biocon Developing Own Version of Wegovy, Plans Clinical Trial
- Indian pharmaceutical company Biocon is working on developing its own version of Novo Nordisk's popular Wegovy and is likely to conduct a clinical trial next year to enter the growing weight-loss drug market.
- Biocon's CEO, Siddharth Mittal, has expressed the company's intention to develop semaglutide, the active ingredient in Wegovy, for the Indian market, even if it requires a clinical trial.
- Biocon aims to introduce generic versions of weight-loss drugs in emerging markets such as Brazil, Mexico, and Saudi Arabia before the patent for semaglutide expires in those countries in 2026.
- The company is striving to obtain a waiver on clinical trials from Indian regulators and submit bioequivalence studies to demonstrate the effectiveness of their version of semaglutide. Biocon is making significant investments in generics research and development, including peptides for weight-loss drugs.
Ad group WPP trails rivals with decline in organic revenue: Britain's WPP became a clear laggard among global ad companies with a drop in organic revenue drop in ...
reuters.com/business/media-telecom/ad-group-wpp-reports-16-drop-first-quarter-organic-growth-2024-04-25/
Lower prices, stubborn costs could weigh on copper miners' quarterly results: North American copper miners are expected to report a decline in first-quarter ...
reuters.com/markets/commodities/lower-prices-stubborn-costs-could-weigh-copper-miners-quarterly-results-2024-04-22/
Quick Glance: Copper Miners Facing Challenges from Lower Prices and Higher Costs
- North American copper miners are expected to report a decline in first-quarter earnings due to lower copper prices and persistently high costs.
- The miners are also grappling with a labor shortage, especially in countries like the U.S., and lower grades of ore, raising per-unit production costs.
- Analysts suggest that a surge in gold prices could provide relief to miners like Freeport, as gold is often mined as a by-product.
- The late rally in copper prices is likely to boost the free cash flow of miners in the second quarter, as predicted by analysts.
Swiss pharma giant Roche's first-quarter sales edge higher as its emerges from post-Covid-19 slump
cnbc.com/2024/04/24/swiss-pharma-giant-roches-first-quarter-sales-edge-higher-as-its-emerges-from-post-covid-19-slump.html
China’s drugmakers can’t sell mRNA shots but haven’t quit yet | The Asahi Shimbun: Breaking News, Japan News and Analysis
asahi.com/ajw/articles/15235088
America’s moves against Chinese biotech will hurt patients at home : The motives behind the BIOSECURE act are muddy
economist.com/leaders/2024/04/18/americas-moves-against-chinese-biotech-will-hurt-patients-at-home
McKinsey Is Under Criminal Investigation for Its Opioid Work: Federal prosecutors are examining the consulting company’s role in helping “turbocharge” the sale ...
nytimes.com/2024/04/24/business/mckinsey-criminal-investigation.html
Quick Glance: Investigation against McKinsey in the US over involvement in the opioid industry
- A grand jury was established to examine evidence related to consulting for pharmaceutical companies involved in the addiction epidemic.
- McKinsey is under a criminal investigation in the US for its involvement with opioid manufacturers.
- Furthermore, federal prosecutors are looking into whether the company impeded justice through its actions as concerns about its work grew.
- According to a source, the US Department of Justice has been scrutinizing McKinsey's activities for several years, with a grand jury now set up in Virginia to review evidence.
Sanofi to overhaul US operations of vaccines, cut jobs: French drugmaker Sanofi said on Thursday it would restructure the U.S. commercial operations for its ...
reuters.com/business/healthcare-pharmaceuticals/sanofi-overhaul-us-operations-vaccines-cut-jobs-2024-04-18/
WHO likely to issue wider alert on contaminated J&J cough syrup: The World Health Organization is likely to issue a wider warning about contaminated Johnson and ...
reuters.com/business/healthcare-pharmaceuticals/who-says-wider-alert-contaminated-jj-cough-syrup-likely-2024-04-19/
Alzheimer’s drug Leqembi falls short of blockbuster status in faltering US rollout
ft.com/content/1e02c10c-f7c4-48e9-a6a4-774531b56350
Medicare beneficiaries could be eligible for Wegovy coverage, study shows
reuters.com/business/healthcare-pharmaceuticals/about-36-mln-medicare-beneficiaries-could-be-eligible-wegovy-coverage-study-2024-04-24/
BASF boss Brudermüller: Germany is not out of the crisis, it is falling behind: Martin Brudermüller imagined his six years at the helm of the German chemical ...
nzz.ch/wirtschaft/basf-chef-brudermueller-2023-haben-wir-in-allen-maerkten-geld-verdient-ausser-in-deutschland-ld.1826608
David Egilman, Doctor Who Took On Drug Companies, Dies at 71: His testimony as an expert witness in some 600 trials helped plaintiffs win billions of dollars in ...
nytimes.com/2024/04/15/health/david-egilman-dead.html
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents: The U.S. Supreme Court on Monday declined to hear a bid by Vanda Pharmaceuticals ...
reuters.com/legal/us-supreme-court-rejects-vanda-pharmaceuticals-case-over-sleep-drug-patents-2024-04-22/
Pharmaceutical giant Bayer is getting rid of bosses and asking nearly 100,000 workers to ‘self-organize’ to save $2.15 billion
fortune.com/europe/2024/04/11/pharmaceutical-giant-bayer-ceo-bill-anderson-rid-bosses-staff-self-organize-save-2-billion/
Paid articlePaid Africa’s Biggest Drugmaker Aspen Can Help Ease Obesity Medicine Supply Crunch: Africa’s biggest drugmaker could potentially help ease a growing supply crunch for ...
bloomberg.com/news/articles/2024-04-22/africa-s-biggest-drugmaker-aspen-can-help-ease-obesity-medicine-supply-crunch
Rwanda joins other African countries in recalling J&J children's cough syrup: Rwanda's drug regulator has recalled a batch of Johnson & Johnson children's cough ...
reuters.com/world/africa/rwanda-joins-other-african-countries-recalling-jj-childrens-cough-syrup-2024-04-15/
Novavax investor Shah Capital pushes for board shakeup: Novavax shareholder Shah Capital is pushing the vaccine maker to add two of its nominees to the board to ...
reuters.com/business/healthcare-pharmaceuticals/hedge-fund-shah-capital-recommends-two-new-candidates-novavax-board-2024-04-15/
Quick Glance: Criticism of Novavax for Missed Opportunities in Boosting COVID-19 Vaccine Sales
- Shah Capital called for immediate changes in the company's board.
- The activist hedge fund Shah Capital criticized Novavax's leadership for not capitalizing on concerns some individuals have about mRNA vaccines to increase sales of its traditional, protein-based COVID-19 vaccine.
- Findings from a survey of 1,500 Americans by the Annenberg Public Policy Center (APPC) at the University of Pennsylvania revealed an increase in the spread of vaccine misinformation.
- The limited use of COVID-19 vaccines is also affecting other vaccine manufacturers. In the U.S., only 14% of adults have received an updated COVID-19 vaccine for 2023-2024, according to the Centers for Disease Control and Prevention.
America hits Chinese biotech—and its own drugmakers: A sweeping bill in Congress could cost patients at home
economist.com/business/2024/04/15/america-hits-chinese-biotech-and-its-own-drugmakers
The Dow jumps 175 points as the markets look to break a losing streak: Bank of America, Morgan Stanley, and Johnson & Johnson all reported earnings before the ...
qz.com/dow-jones-stock-market-inflation-losing-streak-earnings-1851412882
Paid articlePaid
Bayer CEO is getting rid of bosses: Bayer CEO Bill Anderson may be setting the tone for a new workplace trend.
thestreet.com/employment/bayer-ceo-is-getting-rid-bosses-employees-self-manage
Boehringer replaces Bayer as Germany's largest drugmaker on Jardiance gains: Boehringer Ingelheim on Tuesday overtook Bayer as Germany's largest drugmaker when ...
reut.rs/3xKzeFg
How to fix a faulty microbiome: Our podcast on science and technology. From faecal transplants to microbial medicines, we consider the prospects for a new kind ...
economist.com/podcasts/2024/04/17/how-to-fix-a-faulty-microbiome
Paid articlePaid Blackstone nears deal to sell S.Korean pharma wholesaler to MBK Partners, sources say
reut.rs/3U84zcy
Galderma CEO Says Skincare Firm Can Fix ‘Ozempic Face’ With Fillers: Galderma Group AG’s boss has an answer for people suffering from sunken faces after taking ...
bloomberg.com/news/articles/2024-04-24/we-can-fix-your-ozempic-face-says-skincare-firm
Chemical industry: BASF launches the world's first electric steam cracker - Golem.de
golem.de/news/chemische-industrie-basf-startet-weltweit-ersten-elektrischen-steamcracker-2404-184321.html
McKinsey faces US criminal investigation over its opioids work: McKinsey & Co is under criminal investigation in the United States over allegations that the ...
smh.com.au/business/companies/mckinsey-faces-us-criminal-probe-over-opioids-work-sources-say-20240425-p5fmih.html
ICYMI! Watch the Splash with MASH replay to learn which patients are most at risk for metabolic dysfunction-associated steatohepatitis, or MASH ... Show more
A Splash With MASH
A Splash With MASH
Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper
reuters.com/business/healthcare-pharmaceuticals/spanish-drug-maker-grifols-will-bring-independent-directors-chairman-tells-2024-04-14/
The first OTC birth control pill is taking center stage at the WNBA draft: The WNBA draft will mark the beginning of a multi-year sponsorship of the league by ...
fastcompany.com/91091953/wnba-opill-sponsorship-draft
J&J's medical device sales fall short, cancer drugs seen growing: Johnson & Johnson's first-quarter revenue missed Wall Street estimates for medical devices on ...
reuters.com/business/healthcare-pharmaceuticals/jj-beats-first-quarter-profit-estimates-cancer-drugs-strength-2024-04-16/
Eli Lilly's weight-loss drug Zepbound might help cure your sleep apnea: Eli Lilly and Company announced promising results for its weight loss drug Zepbound ...
f-st.co/zuvlyJn
Drug sales keep beating Wall Street's expectations and boosting some pharma stocks
qz.com/pharma-sales-q1-1851435519
US FDA warns of harmful reactions to fake Botox injections: The U.S. Food and Drug Administration on Tuesday alerted health care professionals and consumers that ...
reuters.com/business/healthcare-pharmaceuticals/us-fda-warns-harmful-reactions-fake-botox-injections-2024-04-16/
Mexico's Galapagos Islands: Unique Oasis Cuatro Ciénegas Dries Up: The ancient oasis of Cuatro Ciénegas is a unique ecosystem with microorganisms from hundreds ...
n-tv.de/mediathek/bilderserien/panorama/Einzigartige-Oase-Cuatro-Cienegas-trocknet-aus-article24840174.html
Biogen Alzheimer’s drug sales beat expectations: The Cambridge firm on Wednesday reported a first-quarter profit that exceeded estimates as it cut costs and ...
bostonglobe.com/2024/04/24/business/biogen-alzheimers-drug-leqembi/
WHO warns of falsified cough syrup ingredients seized in Pakistan: The World Health Organization issued an alert on Monday warning drugmakers of five ...
reuters.com/world/asia-pacific/who-warns-falsified-cough-syrup-ingredients-seized-pakistan-2024-04-15/
Bayer recalls hydraSense baby product over 'potential contamination': Bayer announced Thursday it is recalling two lots of its hydraSense Baby Nasal Care ...
ctvnews.ca/health/bayer-recalls-hydrasense-baby-product-over-potential-contamination-1.6853118
Always wanted to know more about foraging for your own food? 🌿
In episode one of our brand-new series, Wild Garlic Weekly ... Show more
Wild Garlic Recipes | Good Food
Wild Garlic Recipes | Good Food
Procter & Gamble hiked prices — and then Pampers and Bounty sales dipped: The company's stock fell slightly after net sales failed to meet analysts' expectations
qz.com/procter-gamble-earnings-sales-pampers-bounty-price-hike-1851422040
New to NewsWall?
Sign up now to get your own personalized news!
Trending topics